Possible evidence for care and treatment in the Tyrolean Iceman

Is Target-Based Drug Discovery Efficient? Discovery and "Off-Target" Mechanisms of All Drugs

Target-based drug discovery is the dominant paradigm of drug discovery; however, a comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic review of about 32000 articles and patents dating back to 150 years ago demonstrates its apparent inefficiency. Analyzing the origins of all approved drugs reveals that, despite several decades of dominance, only 9.4% of small-molecule drugs have been discovered through "target-based" assays. Moreover, the therapeutic effects of even this minimal share cannot be solely attributed and reduced to their purported targets, as they depend on numerous off-target mechanisms unconsciously incorporated by phenotypic observations. The data suggest that reductionist target-based drug discovery may be a cause of the productivity crisis in drug discovery. An evidence-based approach to enhance efficiency seems to be prioritizing, in selecting and optimizing molecules, higher-level phenotypic observations that are closer to the sought-after therapeutic effects using tools like artificial intelligence and machine learning.

The Bioarchaeology of Disability: A population-scale approach to investigating disability, physical impairment, and care in archaeological communities

OBJECTIVE

This research introduces 'The Bioarchaeology of Disability' (BoD), a population-scale approach which allows for a comprehensive understanding of physical impairment and disability in past communities through a combination of palaeopathological, funerary, and documentary analyses.

METHODS

The BoD consists of three phases: 1) Contextualisation includes period-specific literature review; 2) Data collection consists of palaeopathological re-analysis of all individuals with physical impairment and collation of mortuary treatment data; and 3) Analysis integrates the gathered data, literature review, and theoretical frameworks to explore contemporary perceptions of disability.

MATERIALS

The BoD is demonstrated through an investigation of physical impairment and disability in later Anglo-Saxon England (c.8th-11th centuries AD) which includes four burial populations (N_total=1543; N_impaired=28).

RESULTS

Individuals with physical impairment could be buried with normative or non-normative treatment (e.g., stone/clay inclusions, non-normative body positioning), and in marginal, non-marginal, and central locations.

CONCLUSIONS

The overall funerary variation for individuals with physical impairment was relatively slight, which may suggest that religious factors were influencing normative funerary treatment of impaired and potentially disabled individuals. The funerary variability that was observed for individuals with physical impairment was probably influenced by individual and community-specific beliefs.

SIGNIFICANCE

This research describes a population-scale approach to archaeological disability studies that can be replicated in other archaeological contexts.

LIMITATIONS

Individuals with non-skeletal physical impairment (e.g., soft tissue, mental) are not considered by the BoD.

SUGGESTIONS FOR FURTHER RESEARCH

The BoD should be applied to different archaeological communities around the world to better understand disability and physical impairment in the past.

Paleomedicine and the Evolutionary Context of Medicinal Plant Use

Modern human need for medicines is so extensive that it is thought to be a deep evolutionary behavior. There is abundant evidence from our Paleolithic and later prehistoric past, of survival after periodontal disease, traumas, and invasive medical treatments including trepanations and amputations, suggesting a detailed, applied knowledge of medicinal plant secondary compounds. Direct archeological evidence for use of plants in the Paleolithic is rare, but evidence is growing. An evolutionary context for early human use of medicinal plants is provided by the broad evidence for animal self-medication, in particular, of non-human primates. During the later Paleolithic, there is evidence for the use of poisonous and psychotropic plants, suggesting that Paleolithic humans built on and expanded their knowledge and use of plant secondary compounds.

Gut Microbiota and Colon Cancer: A Role for Bacterial Protein Toxins?

Accumulating evidence indicates that the human intestinal microbiota can contribute to the etiology of colorectal cancer. Triggering factors, including inflammation and bacterial infections, may favor the shift of the gut microbiota from a mutualistic to a pro-carcinogenic configuration. In this context, certain bacterial pathogens can exert a pro-tumoral activity by producing enzymatically-active protein toxins that either directly induce host cell DNA damage or interfere with essential host cell signaling pathways involved in cell proliferation, apoptosis, and inflammation. This review is focused on those toxins that, by mimicking carcinogens and cancer promoters, could represent a paradigm for bacterially induced carcinogenesis.

European medicinal mushrooms: Do they have potential for modern medicine? - An update

BACKGROUND

The application of mushrooms for health purposes has a long tradition and is very common in Asian countries. This trend is also becoming increasingly popular in the western hemisphere. However, mushrooms from European tradition are being treated in a restrained manner despite having significant potential as drugs or as sources of pure bioactive substances.

AIM

The present review provides an overview of the most important mushrooms used in European ethnomedical traditions and explores their pharmacological potential and the challenges for the development of new drugs from these sources of natural products.

METHOD

Mushroom species were selected based on information in old herbal books and dispensaries, uninterrupted use and scientific literature in the PubMed database up to June 2019.

RESULTS

Traditional experiences and modern studies have demonstrated that medical mushrooms used in European traditions have promising distinct pharmacological potential mediated through defined mechanisms (anti-tumour, anti-inflammatory, anti-oxidative and anti-bacterial). However, the number of modern chemical, biological and pharmacological studies remains relatively small, and some mushroom species have not been studied at all. Unfortunately, no valid clinical studies can be found. Unlike the case with herbal and fungal drugs from traditional Chinese medicine, we are far from comprehensively exploring this potential.

CONCLUSIONS

Mushrooms from traditional European medicine have the potential to be used in modern medicine. Considerable research, interdisciplinary collaboration, involvement of the pharmaceutical industry, time and money are necessary to explore this potential not only in the form of dietary supplements but also in the form of approved drugs.